GENESIS Biomed and GENESIS Ventures · GENESIS Biomed - Corporate Presentation 1 June 2020 GENESIS...

1GENESIS Biomed - Corporate Presentation

June 2020

GENESIS Biomed and GENESIS VenturesCorporate Presentation

Please contact us at:Baldiri Reixac 4, 08028 BarcelonaVelázquez 25, 2º A, 28001 [email protected]+34 93 403 58 53

mailto:[email protected]


01Corporate presentation GENESIS Biomed


01 Corporate Presentation of GENESIS Biomed

Who are we?

GENESIS Biomed is a consultancy firm in the biomedical healthcare sector specialized in providing consulting services to spin-off and start-up companies, entrepreneurs and research centers.

Based in our expertise we help entrepreneurs and researchers to shape their business plan and we support them in the private fundraising process. We have raised >45 M€ in the last years.

We are Associate Partner at EIT Health and we are currently working in 7 EIT Health projects with TOP EU institutions.

Our expertise domains are biopharmaceutical, biotechnological, medical devices, in vitro diagnostic, nutraceutical and cosmetic. With more than 20 years of expertise in the healthcare sector, we are born in May 2017 and we are located in the Barcelona Science Park.

In addition, the company owns GENESIS Ventures, a new fund sized in 2,0 M€ that invests in early stage research projects in the biomedical field, with the aim to accelerate their development and reach key value milestones to found the company and attract a first round of investment from other venture funds.



Our locations: Barcelona and Madrid

GENESIS Biomed HQBarcelona Science Park, Tower I

Baldiri Reixac 408028 Barcelona

Madrid OfficeCalle de Velázquez 25, 2º A

28001 Madrid

We are glad to announce that inSeptember 2019 we have open ournew offices located at Velázquez 25,Madrid.

Located in the real center of Madrid,our new offices will allow us to workclosely with the clients we have inMadrid area.

In the coming weeks we will hire amanager and two consultants for ourMadrid Office.

We will keep our Barcelona staff in 10members, and GENESIS CEO will beworking part time in both offices.


Business PlanPreparation of business plans for spin-off or

start-up companies, taking into account market, positioning, regulatory, development, IP, team

and financials.

Private FundraisingDefinition of the fundraising strategy. Selection

of private investors among a wide personal network and assistance in the fundraising and

negotiation.

Interim CEOFor those start-up companies with an

incomplete team. Serving as CEO and leading the Project until identifying and hiring a full-

time CEO.

Regulatory and Development PlanPreparation of regulatory roadmaps including regulatory strategy and development plans for

biopharma, medtech, diagnostic, nutra and cosmetic.

Strategic PlanPreparation of strategic plans for research

centres and companies, including internal/external diagnostic, vision, strategic

objectives and action plan.

Business DevelopmentFor companies and research centres.

In-licensing and out-licensing activities. Well established BD process built in the last 10 years

+ wide network of contacts.

Market AnalysisPreparation of market and competitors analysis

using robust databases, knowledge management tools and fieldwork (interviews

and focus groups).

Partners in EIT Health and H2020Participation in European consortiums as proactive partners, leading the business,

regulatory and commercial work packages, in EIT Health, H2020, FTI and SME-2

Training & AcademyFor hospitals and research centres.

Provide general knowledge in biomedical entrepreneurship and technology transfer to

researchers and institutions

Strategic follow-up and supervision of current projects – For those companies developing a project after a first capital round, continuous supervision and support in the strategic decision making of the company, serving as Board observer if needed.


Our portfolio of services

1 2 3

6

8 9 10

4

5 7



Our value proposition in fundraising projects: from the Scientific case to the Investment case

Investment case

Business case

Scientific case

In the projects related to fundraising, we always start from the Scientific Case, always excellent that comes from the Research

Group.

We convert it into a Business Case, that is containing all the aspects to be considered in a Business Plan.

Finally, creating a team between GENESIS Biomed and the Research Group, we start a process that helps the investors to

create their Investment case that provides them support in the decision making.



Participation in EU projects as proactive partners

Preparation of Business Plan and Design of Business Model1

Market research and market analysis including fieldwork2

Implantation Plan and Market Access Plan3

Commercialization and Exploitation Plan4

Regulatory roadmap and Regulatory development activities5

Business Development for Licensing / M&A6

Currently working in 12 EU funded projects. We become very proactive partners in the preparation of the proposal and in the hearings. We are also a high proactive business partner during the development of the project.


GENESIS Biomed becomes EIT Health Associate Partner

Innovation Pillar

GENESIS Biomed can contribute to take part as a consortium member in Innovation by Ideas or Innovation by Design projects.

The main tasks to be carried out will be:• Business plans• Business coaching• Commercialization• Business development• Preparation of WP0• Etc

Acceleration Pillar

GENESIS Biomed will apply to the appropriate calls in which our expertise can contribute for the Pillar, such as bootcamps, Market Coach Network, Investors network, Crowdfunding

platform, Catapult, etc.

Campus Pillar

We can also contribute in Campus projects by preparing Sustainability Plans or Bootcamps.

We have become Associate Partner

at EIT Health on May 14th 2018


We have also become Members of the

Spanish Management Board at EIT Health


EIT Health, the main biomedical European network with TOP companies and institutions


Our presence in EIT Health as Associate partner allows us to collaborate with TOP

international institutions

In the last months we have started 8

international projects



Our current client portfolio (1/3)

Big & mid-sizeSpin-off and start-up

https://www.google.es/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&ved=2ahUKEwi5lO_Rpo_iAhVNzYUKHbo7C6IQjRx6BAgBEAQ&url=https%3A%2F%2Fwww.infectiepreventieopleidingen.nl%2Fdownloads%2Fpresentaties%2Flbok18%2F04_bill_passmore_optimus.pdf&psig=AOvVaw08dj4pw3QZCyuhsDlBigcS&ust=1557520631762268




Academia & Research




Investors InstitutionalHealthcare

https://www.google.es/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjP__i25erdAhUShxoKHUf0CIoQjRx6BAgBEAU&url=https://www.audea.com/es/project/dia-2/&psig=AOvVaw3cxV9d0aJ8cQBm0j3sukaE&ust=1538673976483638

https://www.google.es/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&ved=2ahUKEwjjwZfo7pDiAhUTAWMBHSL3BNUQjRx6BAgBEAQ&url=https%3A%2F%2Fwww.caixaimpulse.com%2Fdocuments%2F20182%2F56365%2FRulesforparticipationCI017_def_V3.pdf%2F87620f6e-11bd-f7c0-4088-f10d6b059e6f&psig=AOvVaw1PhTdySSDZbqNfTjZFkxsH&ust=1557574363498257



GENESIS team @ Barcelona Office: 10 very committed and passionate people

Josep Lluís FalcóManaging partner & CEO

Chemist PhD, MBA

Natalia de la FigueraManaging partner & COO

Chemist PhD, PMP®

Jordi OrtizSenior Consultant

Chemist

Berta BorràsConsultant

Biotech. and Biochemist

Mireia SamitierConsultant

Biologist

Gisela GallegoConsultant

Biotechnologist

Anna MiróConsultant

Biomedical Sciences

Alberto RodríguezConsultant trainee

Biotechnologist

Mariona CostaConsultant trainee

Biotechnologist

Teresa BauComms Manager

Journalist & Digital MKT


Josep Lluís Falcó. Doctor in Chemistry (Institut Químic de Sarrià) and MBA (Universitat de Barcelona).

Josep Lluís has 21 years of experience in the biomedical sector. He has worked for big pharma companies (Sanofi), mid-size pharmas(Ferrer Grupo), small biotechs (Hospital spin-off), Tech Transfer Offices (Fundació Bosch i Gimpera) and Consulting firms (AntaresConsulting and Asphalion). He has also been associate professor at IQS.

His experience is based in Healthcare Strategy, Technology Transfer, Fundraising of start-up companies, Business Development, Marketing,Market Access, Reimbursement and Regulatory Affairs.

Josep Lluís has founded 4 companies. He currently serves as board member for 5 start-up companies and he is mentor of severalentrepreneurs. In addition in the last 5 years he has been involved in 11 private fundraising processes and he has contributed to raise 42million euros for his clients.

The projects in which Josep Lluís has been involved are based in small chemical entities, biologicals, diverse medical devices, in vitrodiagnostics, nutraceuticals and cosmetics.

The therapeutic areas where he has recently worked are Oncology, Central Nervous System, Cardiovascular, Ophthalmology, Orthopedics,Traumatology, HIV, Microbiome, Antibacterials and Immunomodulation.

He has global knowledge of drug/device development, having worked in Discovery, Preclinical and Clinical phases, Marketing and Post-Marketing.

He takes part of programs such as Caixa Impulse and EIT Health programs, participating as reviewer, mentor and professor.

The entrepreneurial spirit runs through his veins. He has founded GENESIS Biomed to help other entrepreneurs and research centers intheir current projects.

Josep Lluís FalcóManaging partner and [email protected]


A highly committed team



Natalia de la FigueraManaging partner and [email protected]



Natalia de la Figuera. PhD in Chemistry, Master in Project Management, PMP®

Natalia has developed her professional experience both in academic (CSIC Madrid and Barcelona) and in thepharmaceutical industry: big pharma (Fresenius Kabi, Sanofi, Lilly, Merck-Serono), mid-size (Almirall, Palau Pharma)and start-ups (Ojer Pharma, ImmunNovative Developments, Enantia).

She has worked in different positions in areas as project management, regulatory affairs, R & D and Quality amongothers.

The main therapeutic areas on which she has been involved were oncology, central nervous system, anti-inflammatory,antibacterial, autoimmune diseases and cardiovascular.

From 2015 she has been focused mainly in project management, broadening her knowledge on economic-administrative monitoring and controlling, changes request and dissemination results of projects.

During her last job in the FSJD (Fundació Sant Joan de Déu) she was involved on public funding projects, some of themcollaboratives, allowing her to acknowledge another health environment.

She joins GENESIS Biomed in April 2019. She is a passionate of improving health and quality life for patients



Jordi OrtizSenior [email protected]



Jordi Ortiz. MSc in Chemistry, Biochemistry field (Universitat de Barcelona)

He completed his Master Thesis in Cation-induced aggregation and fusion of N-acyl-N-methylphosphatidyl-ethanolamine liposomes and continued his research by studying the lipid-protein interaction.

In 1994, he joined the pharmaceutical industry and has occupied several positions, always in the R&D area (fromDiscovery to Clinical phases). He has worked in Sanofi, Ferrer and Spherium Biomed. In this last company he has holdthe position of Senior Project Manager working in several projects from the discovery phase until the clinical researchphase.

He has an extended experience in several management positions in regulated analysis laboratories and as projectmanager with both large and small molecules.

During the last years, he has been working in Autoinmune Diseases, Muscle recovery, ALS, Oncology Mucositis andAcute Kidney Injury.

Jordi has also a deep expertise in European public fundraising and in Business Development activities, all of themrelated to the projects in which he has participated.

He joins GENESIS Biomed in March 2019. He is a passionate of biomedical innovations of academic origin in order toaccelerate their transition to the market.





BSc in Biotechnology (Universitat Autònoma de Barcelona, 2012), BSc in Biochemistry (Technische UniversitätHamburg-Harburg, 2013) and Master in Pharmaceutical Industry and Biotechnology (Universitat Pompeu Fabra,2015).

Berta has worked for 2 years at the Tech Transfer Office of IDIBELL (Institut d'investigació Biomèdica de Bellvitge).Her fields of expertise are project management, fundraising and technology transfer. Previously, she worked as anintern at some R&D laboratories (Esteve, Charité, Humboldt University of Berlin and IMIM).

She joins GENESIS Biomed in May 2018. Science is her passion and she seeks to help entrepreneurs start their ownbusiness.

Berta BorràsConsultant

[email protected]

BSc in Biotechnology (Universitat de Vic, 2011) and Master in e-Health (Universitat Oberta de Catalunya, 2015).

In the last two years Gisela has worked in the Tech Transfer and Innovation Office of Sant Pau Research Institute,with expertise in IP management and business development. She has three years of previous experience in e-HealthProject Manager as well as QMS Responsible at an ICT SME for the health sector.

She joins GENESIS Biomed in September 2018. Passionate about e-health and biotechnology, she seeks to helpentrepreneurs to bring innovation to society.

Gisela GallegoConsultant

[email protected]






BSc in Biology (Universitat de Barcelona, 2013) and Master in Genetics and Genomics (Universitat de Barcelona,2014).

In the lasts three years Mireia has worked as research assistant in various stem cell projects in the field of heart andand kidney differentiation in IBEC (Institut de Bioenginyeria de Catalunya).

She joins GENESIS Biomed in June 2018. She loves science and looks forward to support the creation of new start-ups in the biomedical field.

Mireia SamitierConsultant

[email protected]

BSc in Biomedical Sciences (Universitat de Lleida, 2018) and Master in Management of Biotech companies atCESIF.

Anna has experience as a research assistant in some different areas (biophysics, neuroscience and pathologicalanatomy) in laboratories belonging to University of Pécs (Hungary), Universitat de Barcelona and HUAV Lleida. Shedeveloped her final dissertation in IDIBAPS (Barcelona) studying the role of nutrigenomics in the progression of type2 diabetes. She has finished a Master in Management of Biotech companies (CESIF), acquiring all the necessaryknowledge to develop her skills in the sector.

Anna joins GENESIS Biomed in March 2019. She is willing to assist entrepreneurs in the establishment of their newinnovative companies.

Anna MiróConsultant

[email protected]






Alberto RodríguezConsultant trainee

[email protected]

BSc in Biotechnology (Universitat de Barcelona, 2019) and MSc in Technology and Management of Biotechcompanies (CESIF, 2020).

Alberto has experience as an undergraduate researcher in laboratories belonging to the University of Cologne(Germany). He developed his Bachelor´s Thesis in CECAD (Cologne) studying ubiquitin and its effect on cellularregulation and homeostasis under stress conditions, under the supervision of Dr. Mafalda Escobar-Henriques Dias.Eager to acquire and develop his career in Biotech based companies' management he is attending to a Master´sDegree in Technology and Management of such companies at CESIF. Alberto joins GENESIS Biomed in January 2020.With his scientific background he looks forward to help in the development of spin-off and start-up companies,considering technology transfer as a tool of innovation.

Mariona CostaConsultant trainee

[email protected]

BSc in Biotechnology(Universitat de Barcelona, 2019) and Master in Management of Biotech companies at CESIF.

Mariona studied Biotechnology and is currently attending a Master in Management of Biotech companies at CESIF inorder to assist the establishment and growth of small biotechnological companies. She performed her final degreeproject in the Spin-off DBGen Ocular Genomics where she performed tasks related to the optimization of InheritedRetinal Disorders’ genetic diagnose.

She joins GENESIS Biomed in January 2020. She is passionate of Life Sciences and looks forward to support spin-offand start-up creation.






Teresa BauCommunications Manager

[email protected]

Degree in Journalism (Universitat Autònoma de Barcelona), postgraduate course in Medical Communications (Universitat PompeuFabra), Translation Studies at Universitat Autònoma and University of Glasgow and Digital Marketing in ESADE.

Teresa has over 15 years experience as a reporter and communications specialist, mainly working for the healthcare sector, with a focuson digital health. In the last years she has worked for organizations such as Novartis, HIMSS Europe, Patient Power, UOC eHealthCenter, UpToDate, Among Doctors, Mobile World Capital.

Teresa’s areas of expertise include digital communications, social media, communications strategy, content production, digitalmarketing, media relations, PR, Patient Engagement. She has a large network of contacts in the health sector at a national andinternational level. She is a member of the Catalan Association of Scientific Communication and the Journalists College.

Teresa joins GENESIS Biomed in January 2020.



Our Scientific Advisory Board


Dr. Rafael SimóExpert in Endocrinology

Chair of the Division of Endocrinology and Nutrition at Vall d’Hebron University Hospital; Director of Diabetes and

Metabolism Research Unit at Vall d’Hebron Research Institute (VHIR); Professor of Medicine & Endocrinology at the

Autonomous University of Barcelona.

Dr. José Luís MolinuevoExpert in Neurology

Scientific director and Head of the Clinical, Biomarker and Risk Factors Research Group at the Barcelonabeta Research Centre

(BBRC); associate professor in University Pompeu Fabra.

Dr. Francisco Fernández AvilésExpert in Cardiology

Full Professor of Cardiovascular Medicine at the ComplutenseUniversity (UCM); Chairman of the Department of Cardiology in the University Hospital Gregorio Marañón of Madrid; Scientific

Director of the Spanish Network Centre for Cardiovascular Research (CIBERCV).

Dr. Pere GinésExpert in Hepatology

Chairman of Liver Unit, Hospital Clinic Barcelona; Full Professor of Medicine, University of Barcelona; Director of Liver Transplantation; Head of Research Group, IDIBAPS and

CIBEReHD.

Dr. Rafael CantónExpert in Infectious Diseases

Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal; associated Professor of Clinical

Microbiology at Complutense University of Madrid.

Dr. Josep TaberneroChairman of the Board – Expert in Oncology

Head of the Department of Medical Oncology in Vall d’Hebrón University Hospital; Director of the Vall d’Hebrón Research

Institute in Oncology.



The needs we understand for a fundraising process with a startup. Our Methodology

For a fundraising process with a given startup, there are some important steps to accomplish prior starting the roadshow. For that purpose, an Interim CEO should lead the fundraising process, including:

• Business plan preparation and cash need dimension

• Fundraising strategy set up

• Selection of the most suitable VCs for the fundraising, taking care of:

• Lifecycle of the current funds

• Lifecycle of the invested projects

• Portfolio of invested projects

• Preparation of the roadshow with investors

• Starting of the fundraising process:

• Non-confidential approaches and contacts

• First TCs and meetings

• Signature of NDA

• Starting of building the syndicate up

• Negotiation of the Term Sheet

• Creation of a Data Room and coordination of the Due Diligence

• Negotiation of the Investment and Shareholders Agreement

• In the meanwhile, identification of the full-time CEO that will join the spin-off company



Our Methodology. Which are the 10 success factors to learn and implement? (1/5)

1. Market Analysis• Current unmet medical need• Epidemiology• Determination of market size• Description of market trends• Analysis of main players in the market (commercial products)• Description of the future competitors (development projects)

2. Competitive positioning• Analysis of main features of current and future competitors• Price analysis• Business model analysis• Market share analysis• Voice of Customer and Cost-effectiveness analysis• Competitors matrix




3. Proof of Concept results• Complete list and description of studies done till date• Main results obtained and conclusion analysis• Studies to be conducted in the future• Current agreement with the Main Institution• Outsourced studies and external collaborations• R+D Gantt chart

4. Intellectual Property• List of filed patents till date• Analysis of the current situation of each filed patent• List of potential future patents in the project• Freedom to operate analysis• License Agreement from the Institutions• IP strategy of the company




5. Regulatory Strategy• Regulatory framework for the current project• Analysis of the corresponding guidelines and directives• Current regulatory considerations• Future trends and regulatory changes• Regulatory strategy and validation• Regulatory roadmap

6. Development plan• List of all needed studies for the development of the product• Gantt chart for the whole development process• Identification of main milestones• Measurement of timelines• Identification of potential outsourced partners• Prediction of associated costs




7. Internal team of de company• Existing team and initial roles• Presence of a full-time CEO• Complete job description for all needed roles in the future• Organigram analysis and Headcount evolution in the company• Analysis of salaries and ESOP for internal staff• Partners Agreement, Governance and Reserved matters

8. External team• Profiles needed for the Scientific Advisory Board• Design of the Board of Directors• Identification of the Chairman• Identification of suitable outsourced roles and service providers• Analysis of costs and quotations• Design of ESOP for key external people




9. Financial Plan• Definition of the Business Model of the company• Quantification of the global cash need• General Risk Analysis and mitigation plan• Main financial milestones and Identification of Tranches• Fundraising strategy for Investors and Exit scenario analysis• Valuation of the company and Cap Table analysis• Preparation of the Financial Plan: CF, P&L and BS

10. Strategy and Fundraising negotiation• Selection of the most suitable investors• Preparation of the slide deck of the company• Roadshow and first meetings round• Building the syndicate up• Analysis and negotiation of the Term sheet• Preparation of Data room for Due diligence• Negotiation of the Investment Agreement and Partners Agreement• Closing of the Round



Last success cases in fundraising. Our Track record

Signed deals Sector Round size Year Investors

AptaTargets Pharma 4,5 M€ 2017 Caixa Capital Risc, Inveready

Anaconda Biomed Medtech 15 M€ 2017 Ysios, Omega, Innogest, BSabadell

Peptomyc Biotech 4,2 M€ 2017 ALTA Life Sciences, Healthequity

GlyCardial Diagnostics IVD 3,1 M€ 2017 Caixa Capital Risc, Healthequity

MJN Neuroserveis Medtech 750 k€ 2018 Ship2B and Family Offices

Cornea Project IVD 300 k€ 2018 Industrial partner

Corify Care Medtech 1 M€ 2019 Family Office and EU Funds

Oxolife Pharma 300 k€ 2019 Family Office

Cornea Project IVD 300 k€ 2019 Family Office

LiverScreen Project Medtech 8,5 M€ 2019 EU Funds

CreatSens IVD 750 k€ 2019 EU Funds

ABLE Human Motion Medtech 2,5 M€ 2019 EU Funds


Our success stories in fundraising

• Biotech project: recombinant protein for NSCLC and TNBC• 4,2 M€ raised in July 2017• Investors: ALTA Life Sciences and Healthequity

• Pharma project: new aptamer for ischemic stroke• 2,7 M€ raised in May 2017• Investors: Caixa Capital Risc and Inveready

• Medtech project: new catheter for thrombectomy• 15 M€ raised in May 2017• Investors: Ysios, Omega, Innogest, Banc Sabadell

• IVD project: new biomarker for cardiovascular ischemia• 2,4 M€ raised in October 2017• Investors: Caixa Capital Risc and Healthequity


• Medtech project: stratification of patients suffering from atrial fibrillation• 1 M€ raised in January 2019• Investors: Family offices and EU funds



Current projects in fundraising process

Company sector Product Indication Round size

Ophtalmology IVD Cornea disorders 3,6 M€

Cardiovascular Medtech Atrial fibrillation 15 M€

Nephrology IVD Renal failure 300 k€

Women’s health Pharma Fertility 8,1 M€

Gastrointestinal Medtech Chronic Constipation 5 M€

Ophtalmology Pharma Retinitis pigmentosa 500 k€


02Presentation of our new fund GENESIS Ventures


02 Presentation of GENESIS Ventures

Context and need for a New Fund in Tech Transfer (1/2)

Month -12… Month -6 Month 0 Month 6 Month 12

GENESIS Biomed starts working with a client coming from hospital, university or research

center

After the work done by GENESIS, the project is

ready to start roadshow with VC investors

The startup is founded and the financial round

is closed. The project development starts…

Business plan preparation

Interim CEOFundraising

supportGeneral

support…

Activities for GENESIS Biomed during this year

GAPProjects need to be valorised



Context and need for a New Fund in Tech Transfer (2/2)

Questions related to this GAP:

1. All researchers lack of funds for the valorisation of their projects

2. Usually the researchers are not business oriented when deciding which studies to perform

3. With funds & advise, the GAP can be shortened and the project can be ready to start the fundraising process in advance



Lifecycle and portfolio management for GENESIS Ventures

GENESIS Ventures invests in the

research project

The spin-off is founded and GV

becomes shareholder

Period of time in which the ticket will be devoted to the valorisation of the research project (new experiments to generate new results to increase the project value)

Period of time in which GENESIS Biomed will support the spinoff (potential GENESIS’ client) in the fundraising process to finally close a series A with Venture Capital

The series A is closed with VC investors. GV remains as

shareholder until the exit



Investment policy with a given identified project that will become spin-off in 1 year

Our Total Fund: 2,0 M€

Investment Agreement is signed with Research Center and

Research Group

Max. time to found NewCo*: 1 year

After the investment period, the spinoff company should be founded. If the spinoff is not founded and the project is licensed to a third party, the Investment Agreement regulates the return to GENESIS Ventures (via upfront and/or royalties).

In the foundation, GENESIS Ventures acquires the corresponding shares committed in the Investment Agreement. Our policy is not to become a major shareholder.

After the foundation, GENESIS Biomed will help the new spinoff (becoming potential GENESIS’ client) in the fundraising process in order to close a series A with Venture Capital investors.

GENESIS Biomed will manage the projects and will inform the

Investments Committee

Exit scenario: the standard exit scenario for Venture Capital once the Company is acquired or the project is out-licensed to a third party.

Phase 1: Pre-foundation of the spin-off Phase 2: Foundation of the spin-off

* Orientative figures. These will be fixed in a case-by-case basis

Tickets*: 25.000 – 100.000 €



Our invested projects till date

NeuroHealSpinoff UAB

Developing a new therapy for

neuroregeneration

Ticket: 150.000€

ELEMSpinoff BSC-UPC

Developing a new software for

virtualization of human organs

Ticket: 75.000€

Aptamer project

Spinoff IRYCIS

Developing a new aptamer for Breast

Cancer

Ticket: 50.000€

ADmit TxSpinoff IDIBELL

Developing a new IVD for early detection of

Alzheimer Disease

Ticket: 100.000€

MOWOOTStart-up

Developing a new solution for SCI

and chronic constipation

Ticket: 100.000€

Quality Pharma

MedtechSpinoff Karolinska

Developing a new CDSS

Ticket: 100.000€

LIMNOSpinoff CSIC

Developing a new therapy for

retinitis pigmentosa

Ticket: 125.000€

ABLESpinoff UPC

Developing a new exoskeleton for SCI

Ticket: 50.000€

SHBGSpinoff VHIR

Developing a new therapy for obesity

Ticket: 50.000€

CreatSensSpinoff URV

Developing a new IVD for CKD

Ticket: 50.000€

AortyxSpinoff IQS

Developing a new device for aortic

aneurism

Ticket: 100.000€

DropLiteSpinoff ICFO

Developing a new IVD for AH

Ticket: 50.000€


GENESIS Biomed is member of:

©GENESIS Biomed

Barcelona Office:Barcelona Science ParkTower I, offices 3B01-03-05-06Baldiri Reixac 4-808028 Barcelona+34 93 403 58 53

Madrid Office:Velázquez 25, 2º A28001 Madrid

[email protected]


GENESIS Biomed and GENESIS Ventures · GENESIS Biomed - Corporate Presentation 1 June 2020 GENESIS...

Documents

Transcript of GENESIS Biomed and GENESIS Ventures · GENESIS Biomed - Corporate Presentation 1 June 2020 GENESIS...